Turning point of organoid transplantation:first-in-human trial of iPSC-derived retinal organoid grafting in patients with retinitis pigmentosa  

作　　者：Chang-Jun Zhang Zi-Bing Jin 

机构地区：[1]Beijing Institute of Ophthalmology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China

出　　处：《Science China(Life Sciences)》2024年第5期1082-1084,共3页中国科学（生命科学英文版）

基　　金：partly supported by the National Science Fund for Distinguished Young Scholars(82125007)。

摘　　要：The discovery of induced pluripotent stem cells(iPSCs)has revolutionized the field of disease research,providing a promising platform for studying various conditions.Over the last decade,significant progress has been made in combining iPSCs with other cutting-edge technologies to investigate disease mechanisms and develop potential treatments.

关 键 词：conditions PATIENTS RETINITIS 

分 类 号：R318[医药卫生—生物医学工程] R779.6[医药卫生—基础医学]